



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES

Bob Wise
Governor

Paul L. Nusbaum
Secretary

West Virginia Department of Health and Human Resources
Bureau for Medical Services

Pharmaceutical and Therapeutics (P & T) Committee

June 21, 2006 – 3:00 p.m. – 5:00 p.m.

Diamond Building
Rooms B10 & B11
Charleston, West Virginia

MINUTES

Members Present:

David Avery, M.D.
John D. Justice, M.D.
Steven R. Matulis, M.D.
Barbara Koster, MSN, RNC-ANP
Michael Grome, PA-C
Scott Brown, R.Ph.
Rodney Fink, D.O.
Teresa Frazer, M.D., FAAP
Ahmed Faheem, M.D.
Jeffrey Ashley, M.D.

Members Not Present

James Bartsch, R.Ph.
Teresa Dunsworth, PharmD
Kristy H. Lucas, PharmD
Harriet Nottingham, R. Ph.
Gretchen Oley, M.D.

DHHR/BMS Staff Present

Nancy Atkins, Commissioner
Nora Antlake, Counsel
Sandra Joseph, M.D., Medical Director
Peggy King, Pharmacy Director
Gail Goodnight, Rebate Coordinator
Vicki Cunningham, DUR Coordinator
Lynda Edwards, Secretary

Contract Staff/Provider Synergies Present:

Steve Liles, PharmD

Other Contract Staff/State Staff Present:

Stephen Small, RDTP
Shana Phares, State Pharmaceutical Advocate

Present:

AstraZeneca: Crystal Miller, JoAnn Shoup

Boehringer Ingelheim: David Large

Bristol-Myers Squibb: Cindy Kraus,

Eli Lilly: Steve Wolfarth

Genentech: Dusti Prisock

GlaxoSmithKline: Cindy Snyder

Ligand: Malore Smith, B. Haynes

Merck: Larry Swann, Geff Bergh

Organon: Tim Stanley

Ortho McNeil: Nick Rebholz

Pfizer: Jeff Borman, Kent Hunter

PhRMA: Philip A. Reale

Sanofi-Aventis: Walter Gose

Schering-Plough: Brian Hudson

Sepracor: Ryan Payne, Larry Green

TAP: Judy Ricci

Other: Thom Stevens

I. Call to Order

Dr. Steven Matulis, Chairperson, called the meeting to order at 3:15 p.m.

II. Housekeeping

Peggy King, R.Ph., Pharmacy Director, was recognized, and she advised the audience on how the meeting would be conducted.

III. Introductions/ Introductions of New Members

New members were introduced. All parties seated at the table introduced themselves and gave a brief statement about their professional credentials and affiliations.

Mrs. King explained that there would be no therapeutic reviews at this meeting.

IV. Approval of Minutes of February 8, 2006 Meeting

Chairman Matulis asked for approval of the minutes from the last meeting. A motion was made and seconded, votes were taken and the motion carried to approve the minutes as submitted.

V. Purpose/Charge to New Members

Dr. Matulis introduced Commissioner Nancy Atkins. She thanked the Committee members for their service for the last four years and recognized new members. She said that House Bill 466 was passed by the Legislature on March 7, 2002, and signed by Governor Bob Wise. She stated that the purpose of the Bill is to

authorize the Secretary of the Department of Health and Human Resources to develop a Preferred Drug List (PDL) to negotiate and enter into agreements with pharmaceutical manufacturers for supplemental rebates for Medicaid reimbursed drugs. The law also mandates confidentiality of the rebate amounts, records that contain supplemental rebate amounts, and the records of meetings addressing supplemental rebates.

Commissioner Atkins stated that the PDL was created to create cost savings for the Medicaid Program. She said in 2004 the drug expenditure growth was zero, therefore, the Bureau is doing something right. The charge of the Legislation for the Committee is to recommend to the Bureau those drugs that are both scientifically sound, based on clinical information and cost data, and fulfills the spirit of House Bill 466. She stated that the process for the Bureau is to accept or reject the recommendations of the Committee based on all the available information. The Bureau then sends the recommendations to the Secretary, who accepts or rejects the recommendations based on all the available information. She said that implementation of the recommendations is scheduled for the first of the following quarter.

VI. Review of PDL Process

Chairman Matulis introduced Steve Liles and he explained the history of Provider Synergies to the new members. He discussed the process for requesting Supplemental Rebates and the Centers for Medicare and Medicaid Services requirements for coverage of drugs for Medicaid. He said that Provider Synergies will contact pharmaceutical companies and request rebates for the Preferred Drug List. He explained that the cost information is based on federal and supplemental rebates and state's reimbursement policies. Provider Synergies provides this information to the Committee in a grid format, so that they can see exactly what the State is paying for drugs. He reiterated that this information is very confidential and that the relationship with manufacturers and confidentiality of these amounts needs to be maintained. Providers Synergies will also provide the Committee with their recommendations as to what drugs should be preferred or non-preferred. He stated the process then continues with the Committee making their own recommendations based on the clinical and financial data for the classes to the Bureau.

Mrs. King said that there is an Executive Session where the Committee discusses pricing information and it is held in a closed session where the Committee can ask questions. She explained that there would be an Executive Session at the end of the meeting today to educate the new members on the cost sheets so that, when they receive their packets for the August meeting, they can better understand the information that they have received. Dr. Liles said that in the Open Session public comments are limited to discussing the clinical information because the cost information confidentially has to be maintained.

Mrs. King asked Dr. Liles to explain TOP\$ to the new members. He said that West Virginia was one of the first three states, Maryland, West Virginia, and Louisiana, to join a buying group called TOP\$. He said that there are now six states. He explained that increased purchasing power was an incentive for other states to join TOP\$. He said that each state evaluates the information received from TOP\$ individually and makes their own recommendations. It was stated that 1.9 million lives are impacted by the TOP\$ Program.

VII. Reports

Dr. Liles gave an extensive review of the utilization of drugs affected by the PDL for the calendar year. He explained the savings, current pharmacy prescription costs, federal and supplemental rebates for 2006 and how this information relates to the recommendations made for the Preferred Drug List. He discussed the Part D effect on the Preferred Drug List utilization numbers. He said that the drugs that have the largest market share are the ones that Provider Synergies would target and work with the manufacturers, the State, and the Committee to make some changes.

Dr. Liles stated that West Virginia has historically been on of the best states in terms of controlling utilization of preferred drugs, so that 97% of the use of preferred drugs is higher than the use in other states.

VIII. Next Meeting Date – August 16, 2006 (Charleston Civic Center)

Chairman Matulis informed the audience that the next meeting will be held on August 16, 2006. Mrs. King said that the meeting starts at 9:00 a.m. at the Charleston Civic Center and is very well attended and explained to the new members that there would be a bigger audience.

IX. Open to the Floor

It was asked if the audience had any comments.

Cindy Snyder, GlaxoSmithKline, thanked Mrs. King for the accommodations given to speakers at the last meeting, in regards to speakers who did not get a chance to talk by being allowed to submit a two-page document to the Committee. She requested that the two-page comment be limited to text and not references. She said that references could be more than one page. Commissioner Atkins said that would be taken into consideration.

Larry Green, Sepracor, asked about the process for Speaker Sign-up and if changes would be made. Mrs. King stated that the Bureau is required to follow the open meetings law. Due to the interpretation of the law at this time we cannot change the process. Mrs. King said that with the extended time limit for speakers (one hour), more speakers can be accommodated and the Civic Center is more appropriate for the large amount of people.

Chairman Matulis asked for a motion to move to the Executive Session and it was made, seconded and passed.

X. Executive Session

The Committee adjourned to Executive Session where the new members were oriented on the process and policy of the Pharmaceutical and Therapeutics Committee.

XI. Adjournment

A motion was made, was seconded, votes were taken and the motion carried to adjourn the meeting of the Pharmaceutical and Therapeutics Committee.